Anadrol 50mg-700x700

what is anadrol

Antithrombin III – virusinaktivirovanny antithrombin III concentrate. Antithrombin III is a naturally occurring inhibitor of blood coagulation, acting primarily by inhibiting thrombin and activated Factor X. When combined with heparin inhibitory effect of antithrombin III is enhanced.

Indications Application Antithrombin III shown activity in patients with antithrombin III in plasma less than 70% (congenital and acquired antithrombin deficiency) for the prevention of thrombotic and thromboembolic complications. Also, the use of antithrombin III is shown in the following cases:

  • surgery, pregnancy and childbirth in patients with congenital antithrombin III deficiency
  • lack of or insignificant clinical effect in the treatment of heparin
  • the presence or risk of disseminated intravascular coagulation (for example, associated trauma, septic complications, shock, preeclampsia and other disorders caused by acute consumption coagulopathy)
  • the presence or risk of thrombosis in patients with nephrotic syndrome or inflammatory diseases of the bladder
  • surgery or bleeding in patients with severe liver failure, especially in patients receiving clotting factor concentrates.

Contraindications: Not identified. Hypersensitivity to the drug.

Cautions In the production of products that are made from human blood, it is impossible to completely eliminate the risk of diseases caused by the transfer of infectious agents, including those of unknown origin, with the introduction of the drug. Therefore, donors are selected according to strict criteria, carried out the study and selection of plasma taken, as well as laboratory testing of plasma pools (plasma Security Program). The production process of antithrombin III includes special treatment methods aimed at removing and inactivating viruses (a ten heating the solution at 60 ° C). For production of Antithrombin III is used plasma only healthy donors examination which for antibodies to HIV-1, HIV-2, hepatitis C (HCV), as well as the surface antigen of hepatitis B virus (HbsAg) gave negative results. The level of hepatic transaminases (ALT) donors do not exceed the allowable values. Samples of plasma pool in addition to conventional methods well researched for HIV antibodies, HCV and HbsAg. Further research conducted on the viral genome of HIV, HBV, HCV polymerase chain reaction (PCR). PCR is a highly sensitive method which, unlike the study for the presence of antibodies capable of detecting the virus genome itself. The production process is prohibited, except those of the plasma samples in which PCR analysis did not reveal viral genomes. In addition, according to the Security Plasma Program carried out quarantine of each plasma dose and retrospective analysis that provides complete control over the withdrawal of donors. Efficiency undertaken during the production of security measures has been demonstrated in studies with human immunodeficiency virus (HIV), hepatitis a virus and models of hepatitis viruses B and C (HBV, HCV), as well as non-enveloped virus. Clinical studies conducted in accordance with the criteria of the International Society on thrombosis and haemostasis, as well as pharmaco-epidemiological observations antithrombin III showed no transmission of hepatitis virus preparation (HBV, HCV, or non-a non-B hepatitis) and HIV, while at the time of PCR product has not been tested. Prescribe drugs to pregnant women with caution, after careful assessment of the possible risks and benefits.

Dosage and administration of antithrombin III Dosage depends on the etiology and severity of antithrombin III deficiency. Therefore, before starting therapy should determine the activity of antithrombin III. Normal indicators of activity of antithrombin III in human plasma is 80% – 120%, with a decrease of activity below 70% increased risk of thrombosis. Thus, one should expect since the individual drug dosage to levels of antithrombin III in plasma during periods between the administration of the drug was at least 70%. Typically, patients with congenital antithrombin III deficiency half life time of the drug is about 2.5 days. In acquired antithrombin III deficiency half-life is considerably less in the case of disseminated intravascular coagulation (DIC) may be reduced to a few hours. The duration of therapy is variable and depends on the disease. In general, the use of anti-thrombin III may be terminated after normalization laboratory parameters and / or relief of clinical signs. However, following cessation of therapy must regularly monitor the level of antithrombin III for a sufficiently long time. For determination of antithrombin III in plasma before and during drug therapy, it is recommended to measure the activity of antithrombin III, for example with a chromogenic substrate (amidolytic method).

  1. Disseminated intravascular coagulation Dose Antithrombin III is calculated based on the determination of antithrombin III activity in the plasma of the patient prior to treatment and during therapy every 4-6 hours. The initial dose should be sufficient to achieve plasma levels corresponding to normal (80%) – 120%). Additional doses are needed if the antithrombin III activity decreased below 70%. The dose of antithrombin III is calculated as follows: 1 ME antithrombin III / kg body weight = increase of antithrombin III in plasma levels of 1% When using antithrombin III in combination with heparin, it should be into account that the anticoagulant effect of heparin is potentiated by antithrombin III (see. also “Interactions with other medicines” and “Warnings”).
  2. Other diseases with deficiency of antithrombin III The recommended starting dose for adults with an average body mass ME 1500. The maintenance dose is less than twice the initial and administered at intervals of 8 to 24 hours. However, the dosage hvor hurtigt virker vermox should be adjusted taking into account the individual characteristics that can be determined only at the regular measurement of the activity of antithrombin III in the patient’s plasma. The required dosage of antithrombin III, in the absence of the ICE signs, calculated as follows: 1 ME Antithrombin III / kg body weight = increase in antithrombin III in plasma at 2%

Preparation of solution : After cooking, Antithrombin III solution must be used immediately. Opened vials should not be stored.

  1. Warm the vial closed with a solvent at room temperature (not above 37 ° C).
  2. Remove the protective caps from the vials of lyophilized powder and solvent (Fig. A) and disinfect the rubber stoppers on both vials.
  3. The bundled-sided needle with two fastened together with protective caps. Tear bond (Fig. B) by scrolling and remove a cap. Pierce the free end of the needle stopper of the vial with the solvent (Fig. C).
  4. Remove the protective cap from the other end of the double-sided needle, without touching the needle itself.
  5. Turn the bottle with the solvent and pierce the stopper of the vial of lyophilized powder free end of the needle (Fig. D), insert the needle about half the length. The solvent falls in a bottle with a powder under vacuum.
  6. Separate bottles, removing the needle from the vial with the powder (Fig. E). Easy rocking the vial accelerate dissolution of the powder.
  7. After complete dissolution of the powder to precipitate foam pierce the stopper of the vial with the prepared solution of needle-duct (Fig. F), which is included in the kit. Then remove the needle-duct.

The introduction of the resultant solution : Remove the protective cover from the enclosed filter needle and attach the needle to the sterile disposable syringe. Dial the solution in the syringe (Fig. The G). Remove the needle from the syringe and slowly (maximum speed of administration of 5 ml / min) enter the solution intravenously through the enclosed disposable needle (or system for transfusion). If you use another solution preparation method, use an appropriate filter prevent undissolved protein particles or pieces of rubber stoppers (risk microemboli).

Side effects: As with the introduction of other plasma products, there may be rare anaphylactoid or anaphylactic reactions. In the event of such reactions (eg, fever, rash, nausea, vomiting, asthma, anaphylactic shock) you must stop the introduction of the drug. Mild reaction can be stopped by introducing antihistamines, severe reactions to the development of hypotension require conventional emergency antishock measures.

Cautions Patients with hemorrhagic diathesis, joint use of antithrombin III and heparin increases the risk of bleeding. The use of antithrombin III in combination with heparin anticoagulant therapy enhances the effect of which should be taken into account when calculating doses of heparin. In addition, patients with thrombocytopenia must consider the possibility platelet factor 4 deficit leading to disruption neutralize heparin and thus to increase the risk of bleeding. As a rule, in combination therapy with heparin should regularly monitor the activated partial thromboplastin time (APTT) and adjust the dose heparin. In a joint application with heparin dose of the latter should not exceed the ME 500. In patients with congenital antithrombin III deficiency should be considered the possibility of holding an appropriate vaccination.

Interaction with other drugs

  • the joint application of heparin and antithrombin III, the last effect increases
  • pronounced deficiency of antithrombin III considerably reduces the effectiveness of heparin action.

release Form

  • bottle containing 500 ME lyophilized antithrombin III
  • a vial containing 10 ml of water for injections
  • set for preparation of the solution (expenditure needle, needle filter, needle adapter, the needle duct, infusion system).

in a cardboard box with instructions for use.

  • flask containing 1000 ME lyophilized antithrombin III
  • a vial containing 20 ml of water for injections
  • set for preparation of the solution (expenditure needle, needle filter, needle adapter, the needle duct, infusion system).

Running low dose t3 clen cycle trying to lose bodyfat isn’t a real hot idea imo.